The product is a composition of 10mg doxylamine succinate and 10mg pyridoxine hydrochloride (vitamin B6) and is indicated for nausea and vomiting during pregnancy when conservative management fails.
Duchesnay USA chief executive officer, Gilbert Godin, stated that the medicine will become a treatment option for healthcare professionals caring for pregnant women
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia